BNT212
/ BioNTech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 02, 2025
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=375 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Monotherapy • Solid Tumor
August 30, 2025
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=375 | Not yet recruiting | Sponsor: BioNTech SE
Monotherapy • New P1/2 trial • Solid Tumor
1 to 2
Of
2
Go to page
1